| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, LR Chirieac, ... Oncogene 27 (34), 4702-4711, 2008 | 1628 | 2008 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1292 | 2013 |
| LKB1 modulates lung cancer differentiation and metastasis H Ji, MR Ramsey, DN Hayes, C Fan, K McNamara, P Kozlowski, C Torrice, ... Nature 448 (7155), 807-810, 2007 | 1155 | 2007 |
| PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007 | 828 | 2007 |
| A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011 | 705 | 2011 |
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies H Ji, D Li, L Chen, T Shimamura, S Kobayashi, K McNamara, U Mahmood, ... Cancer cell 9 (6), 485-495, 2006 | 529 | 2006 |
| STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment S Koyama, EA Akbay, YY Li, AR Aref, F Skoulidis, GS Herter-Sprie, ... Cancer research 76 (5), 999-1008, 2016 | 510 | 2016 |
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ... Nature 483 (7391), 613-617, 2012 | 496 | 2012 |
| Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor CL Christensen, N Kwiatkowski, BJ Abraham, J Carretero, F Al-Shahrour, ... Cancer cell 26 (6), 909-922, 2014 | 445 | 2014 |
| Somatic LKB1 mutations promote cervical cancer progression SN Wingo, TD Gallardo, EA Akbay, MC Liang, CM Contreras, T Boren, ... PloS one 4 (4), e5137, 2009 | 327 | 2009 |
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ... Cancer discovery 2 (10), 934-947, 2012 | 326 | 2012 |
| Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions ML Sos, K Michel, T Zander, J Weiss, P Frommolt, M Peifer, D Li, R Ullrich, ... The Journal of clinical investigation 119 (6), 1727-1740, 2009 | 323 | 2009 |
| Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors H Ji, X Zhao, Y Yuza, T Shimamura, D Li, A Protopopov, BL Jung, ... Proceedings of the National Academy of Sciences 103 (20), 7817-7822, 2006 | 320 | 2006 |
| Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins T Shimamura, AM Lowell, JA Engelman, GI Shapiro Cancer research 65 (14), 6401-6408, 2005 | 296 | 2005 |
| Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy D Li, T Shimamura, H Ji, L Chen, HJ Haringsma, K McNamara, MC Liang, ... Cancer cell 12 (1), 81-93, 2007 | 265 | 2007 |
| Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors J Carretero, T Shimamura, K Rikova, AL Jackson, MD Wilkerson, ... Cancer cell 17 (6), 547-559, 2010 | 254 | 2010 |
| Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Z Chen, T Sasaki, X Tan, J Carretero, T Shimamura, D Li, C Xu, Y Wang, ... Cancer research 70 (23), 9827-9836, 2010 | 232 | 2010 |
| Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway AB Cortot, CE Repellin, T Shimamura, M Capelletti, K Zejnullahu, D Ercan, ... Cancer research 73 (2), 834-843, 2013 | 221 | 2013 |
| Efficacy of BET bromodomain inhibition in Kras-mutant non–small cell lung cancer T Shimamura, Z Chen, M Soucheray, J Carretero, E Kikuchi, JH Tchaicha, ... Clinical cancer research 19 (22), 6183-6192, 2013 | 217 | 2013 |
| HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy SA Perera, D Li, T Shimamura, MG Raso, H Ji, L Chen, CL Borgman, ... Proceedings of the National Academy of Sciences 106 (2), 474-479, 2009 | 204 | 2009 |
